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Available online 18 July 2016AbstractObjective: To map the progression of osteoporosis following spinal cord injury in mice in specific areas and analyze changes in parathyroid
hormone (PTH) and ion levels which could be responsible for overall bone loss.
Summary of background data: Spinal cord injury rapidly induces severe bone loss compared to other conditions, yet the cause of this bone loss
has not been identified. Studies suggest the bone loss after injury is not solely due to disuse.
Methods: To quantify bone loss we weighed individual bones and measured bone mineral density using dual energy X-ray absorptiometry at
acute (1 week) and chronic (4 week) time points following a T9 contusion. An ELISA was used to measure blood PTH levels at 1 and 4 weeks
after injury. Calcium and phosphate levels were also analyzed at 4 weeks following injury at the University of Miami pathology core.
Results: We observed a significant decrease in bone mineral density in hind limbs after an acute injury, and found this bone loss to progress over
time. Furthermore, following chronic injury a decrease in bone mineral density is also observed in bones above the level of injury and in the total
bone mineral density. We observed a significant decrease in parathyroid hormone levels in injured mice at the chronic time point, but not at the
acute time point which suggests this could be involved in the global bone loss following injury. We also observed a significant increase in serum
calcium levels following injury which could account for the imbalance of PTH levels.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Spinal cord injury (SCI) induces a severe bone loss, putting
patients at high risk for osteoporosis and bone fracture [1e4].
The severe bone loss following SCI differs from osteoporosis
seen in other conditions since it occurs at a much faster rate
[1,4,5]. Following SCI, bone loss has been found to occur at a* Significance: Here we map out the progression of bone loss throughout the
organism following spinal cord injury and measure concurrent changes in
parathyroid hormone, calcium, and phosphate in the blood.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).rate of 1.25% per week and patients can lose up to 41% of
sublesional bone mineral density within the first year [6,7].
The fragility of their skeletons puts SCI patients at a higher
risk for bone fractures despite their lack of physical activity
[1e3]. The incidence of fracture risk increases with time
following injury and can reach up to 39% at 15 years post-
injury [8].
Although it has been previously thought that this bone loss
is mostly due to lack of weight bearing below the neurological
level, recent evidence suggests other factors may be playing a
role. First and foremost, weight bearing exercises seem to have
little to no effect in preventing bone mineral density (BMD)
loss following SCI [9,10]. Secondly, the bone loss rate
following SCI is much higher than that seen in patients who
have undergone microgravity or prolonged bedrest [6,11,12].lsevier B.V. This is an open access article under the CC BY-NC-ND license
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extremities which are still functional [7]. This data underlines
the importance of investigating factors other than lack of
weight bearing which may induce osteoporosis in SCI.
Various ions and hormones in the blood are responsible for
maintaining bone homeostasis. Parathyroid hormone is a key
modulator of bone mass since it is capable of inducing both
bone degradation and bone formation [13,14]. When calcium
levels are low, PTH is synthesized by chief cells in the para-
thyroid gland and activates target receptors on kidneys, gut,
and bones. Upon binding to receptors on bone cells, PTH re-
leases calcium stored within the bone matrix by initiating bone
resorption or bone degradation [15,16]. Osteoclasts are
multinucleated cells which break down the bone during bone
resorption and PTH has been found to increase both osteoclast
activity and levels of bone resorption markers, such as
RANKL, which promote osteoclastogenesis [17,18].
Although parathyroid hormone increases bone resorption, it
simultaneously induces bone formation by activating signaling
pathways in osteoblasts (bone forming cells) which promote
synthesis of the bone matrix. While most therapies for oste-
oporosis are antiresorptive and prevent osteoclast degradation
of the bone, intermittent PTH is the only anabolic therapy
which actually increases bone formation, making it one of the
most effective therapies [13,14,16]. PTH is capable of
changing bone composition leading to bone accrual by
developing both trabecular and cortical bone [19]. PTH ther-
apy has also been found to reduce the risk of fracture in
postmenopausal women with osteoporosis [20,21]. Therefore,
any significant change in PTH levels, whether it be an increase
or decrease, could be causing bone loss following injury.
Previous research has shown aberrant levels of PTH following
spinal cord injury with both increases and decreases depending
on the time after injury [22,23].
Just as PTH regulates serum calcium levels, calcium reg-
ulates the production of PTH through a negative feedback loop
[24,16]. The parathyroid gland contains G-protein coupled
calcium-sensing receptors which regulate PTH synthesis.
Calcium acts as a ligand for these receptors which inhibit the
secretion of PTH upon binding via second messengers such as
calcium and inositol phosphates [16,25]. Therefore, when
serum calcium levels drop, more PTH is produced in order to
restore normal calcium levels and vice versa. Phosphate has
also been found to regulate PTH levels. Hyperphosphatemia
directly stimulates PTH synthesis and phosphate restriction
also prevents growth of the parathyroid gland [26]. Phosphate
and calcium have both been found to bind to PTH RNA ele-
ments and affect its half-life and stability [27].
In this study we characterized the degree of bone loss in
acute and chronic spinal cord injury by measuring BMD at
different time points in naïve and injured mice. After
observing a decrease in BMD, we then quantified blood
plasma PTH levels and serum calcium and phosphate levels at
these time points following injury. Our aim was to characterize
bone loss at different time points following injury and identify
changes in hormone and ion levels which could be responsible
for the corresponding bone loss.2. Materials and methods2.1. AnimalsAdult female C57BL/6 mice were purchased from Jackson
Laboratories (USA) Mice were housed in virus/antigen-free
environments under diurnal lightning conditions and allowed
free access to food and water. Surgeries were performed at
approximately 4 months of age. All experiments were
approved by the Institutional Animal Care and Use Committee
(IACUC Protocol number 11-062).2.2. SurgeryPrior to surgery animals were anesthetized with an IP in-
jection of .02 ml ketamine and .01 ml xylazine. A lam-
inectomy was performed to expose the spinal cord in the T9
vertebrae. Animals were injured by severe contusion with a
predetermined force of 70 k Dynes at T9 delivered by an IH
impactor (Infinite Horizon Impactor IH 0400 by Precision
Systems and Instrumentation), and the exposed area was then
sutured. Post-operative care included daily treatments with
lactated Ringer's solution and gentamycin. Manual bladder
expression was performed daily until needed.2.3. Bone massBones were collected and the muscle was cleaned off
before weighing the bones on a high precision electronic scale
(American Scientific S/P 182).2.4. Dual energy X-ray absorptiometryAnimals were anesthetized with a ketamine and xylazine
cocktail (30 and 10 mg/kg of total body weight) and were laid
down flat, facedown with limbs spread out. Bone mineral
density (BMD) was measured using the pDXA Sabre Bone
Densitometer and the pDXA Sabre Software version 3.9.4
(Norland Medical Systems, Fort Atkinson, WI), both of which
were especially designed for small animals. The research mode
scan option was used for the measurements. Pixel spacing for
the scan was set to 0.5 0.5 mm and the scan speed to 4 mm/s.
We analyzed total BMD, an area defined as the entire skeleton
except for the skull, as well as BMD in certain regions of in-
terest such as the femur, tibia, and humerus. These areas were
defined as the total area from one end of the bone to the other
end of the bone. For each animal both right and left bones were
analyzed and the average of the two was used for analysis.2.5. PTH ELISABlood was collected in EDTA coated tubes and samples
were centrifuged for 15 min at 1000  g within 30 min of
collection. Plasma was removed and an ELISA (Immuno-
topics) kit was used to measure intact parathyroid hormone
(PTH 1e84) levels. Results were normalized to total protein in
the blood which was measured by Lowry assay.
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room temperature before centrifugation. Serum was removed
and analyzed by the University of Miami Comparative Pa-
thology Department.2.7. Statistical analysisStudent's T-test was used to analyze significant differences
between naïve and SCI groups. Paired T-test was used to
analyze significant differences in 1 week post injury and 4
week post injury groups for DEXA imaging data. One way
ANOVA was used to analyze parathyroid hormone levels.
3. Results3.1. Progression of bone loss following injuryWe determined at what time points bone loss can be
observed following thoracic (T9) contusion injury and mapped
the progression of osteoporosis by measuring the extent of
bone loss over time. Four weeks following injury we found
there to be a significant decrease in bone mass below the level
of injury in the tibia (Fig. 1). A significant reduction in BMD
is observed as soon as 1 week following injury, but this is
restricted to areas below the level of injury (Fig. 2). In chronic
injuries (4 weeks), BMD continues to decrease in areas below
injury, and a significant decrease in BMD is also seen in bones
above the level of injury (humeri). A significant decrease is
also seen in the total bone mineral density at this time point.3.2. Decrease in blood PTH levelsIn our mouse model we observed no significant change in
parathyroid hormone levels in blood plasma at one week
following injury, but we did observe a decrease in PTH levelsFig. 1. Bone Mass of hind limbs. Chronically injured mice exhibit a decrease
in bone mass in both the femur and tibia, with a significant decrease in bone
mass the tibia (injured n ¼ 4, naïve n ¼ 4) (p < .05, student's t-test).after four weeks following injury (Fig. 3). Although the PTH
levels appeared to be dropping over time following injury,
there was no significant difference between one week and four
week injured animals.3.3. Increase in blood calcium levelsWe then chose to analyze both calcium and phosphate
levels after injury since these could account for changes in
parathyroid hormone levels. In our animals we found there
was a significant increase in serum calcium levels at 4 weeks
following injury while phosphate levels remained within the
same range (Fig. 4).
4. Discussion
Although osteoporosis is very prevalent within the spinal
cord injury community, the cause of this bone loss has yet to
be identified. In a group of men with SCI, 61% met the World
Health Organization criteria for osteoporosis, and 19.5% were
osteopenic [28]. Patients with spinal cord injury often show
the greatest reduction in bone below the level of injury, but
have also shown bone loss throughout the body [29,30]. Here
we have shown the progression of bone loss following a T9
contusion in mice, which can begin as early as one week
following injury in hind limbs. The total BMD and the BMD
in areas above the level of injury is not affected until chronic
stages of the injury. If bone loss is occurring above the level of
injury where there is still locomotor function, we can deduct
that not all bone loss following injury is caused by disuse or
immobilization. Instead, this data suggests chronic spinal cord
injury evokes a global dysregulation of bone homeostasis not
limited to areas below injury, which directed our focus to
injury induced hormone level changes.
We observed a drop in parathyroid hormone levels only at
the chronic time point after injury which paralleled the pro-
gression of bone loss in areas above the level of injury, but no
significant difference was observed at the acute stage. This
data demonstrates that spinal cord injury has no immediate
effect on PTH levels, but exerts an effect at a chronic time
point. This suggests that the decrease in PTH levels could be
responsible for the total bone loss, but not the local bone loss,
following injury.
After observing a decrease in parathyroid hormone
following injury we decided to investigate different factors
which could be affecting parathyroid hormone levels. Para-
thyroid hormone production is mainly dependent on calcium
levels in the blood. High levels of calcium inhibit PTH syn-
thesis via calcium sensing receptors in the parathyroid gland,
while hyperphosphatemia induces PTH production. We found
that calcium levels were increased after chronic spinal cord
injury which would induce the decrease in PTH levels we
previously observed. Although there was only a 0.48 mg/dL
(0.12 mmol/L) difference in serum calcium levels between
naïve and injured mice, only a very slight shift in calcium
levels is required to induce a massive change in PTH levels. A
study in post menopausal women showed a 1e2% rise in
Fig. 2. Bone Mineral Density in hind limbs, humerus, and throughout the skeleton. A significant decrease in BMD is seen as soon as 1 week after injury in both
tibia (p < .05, Student's t-test) and femur (p < .001, Student's t-test). BMD loss continues to progress at 4 weeks after injury in both hind limbs (p < .05, Paired t-
test). 1 week following injury we see no significant difference in neither total BMD nor BMD in upper limbs. At 4 weeks following injury we see a significant
decrease in BMD in both total BMD (p < .001, Student's t-test) and BMD in upper limbs (p < .01, Student's t-test). (injured n ¼ 5, naïve n ¼ 4).
Fig. 3. Parathyroid hormone levels in the blood. There is a significant
reduction in parathyroid hormone levels in the blood at 4 weeks after injury.
Mean blood plasma PTH levels were 30.65 pg/mg for naïve mice, 20.5 pg/mg
for 1 week injured mice, and 14.25 pg/mg for 4 week injured mice. (p < .01,
One way ANOVA) (naïve n ¼ 8, 1 week injured n ¼ 4, 4 week injured n ¼ 4).
Fig. 4. Calcium and phosphate levels in the blood. There is a significant in-
crease in calcium in the blood at 4 weeks after injury. There is no significant
change in serum phosphate levels after injury. Mean serum calcium levels were
8.38 mg/dL (2.09 mmol/L) for naïve mice and 8.86 mg/dL (2.21 mmol/L) for 4
week injured mice. Mean serum phosphate levels were 8 mg/dL (2.58 mmol/L)
for naïve mice and 8.32 mg/dL (2.69 mmol/L) for 4 week injured mice.
(p < .05, Student's t-test) (naïve n ¼ 4, 4 week injured n ¼ 5).
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data suggests total bone loss observed following chronic SCI
could be caused by changes in calcium and PTH levels.
Currently bisphosphonates are the most common form of
treatment for osteoporosis and function by inhibiting osteo-
clast activity and bone resorption, but these only prevent bone
loss during a certain time frame following injury [32,33]. On
the other hand, PTH is the only molecular compound known to
stimulate bone formation [34]. Targeting PTH production
following injury by manipulating calcium-sensing receptor
activity could be beneficial. Previous studies in rats have
shown that combined treatments for osteoporosis using a
calcium sensing receptor antagonist along with biphospho-
nates are more effective than biphosphonates alone [35].
Although PTH treatment is currently being used to treat SCI
induced osteoporosis, the underlying mechanism as to how it
induces bone anabolism is not completely understood [34].
Although the findings in this study do not fully delineate a
mechanism behind the bone loss following SCI, it is important
to recognize that there is bone loss occurring above the level of
injury and there is a correlation between this global bone loss
and changes in blood PTH and calcium levels. Future studies
should focus on identifying how a loss of PTH following
injury is affecting bone accrual machinery in order to create
effective therapies.
5. Conclusion
At earlier stages (1 week) following injury mice only
exhibit bone loss on the hind limbs but not in the forelimbs.
Chronically injured mice (4 weeks) have significant bone loss
above the level of injury which may be induced by changes in
calcium and parathyroid levels.
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